Aurobindo Pharma Ltd, a leading pharmaceutical company focused on active pharmaceutical ingredients and generic pharmaceuticals, reported a steady Q2FY26 financial performance with revenues rising 6.3% year-on-year to ₹8,286 crore. Consolidated net profit increased by 3.8% to ₹848 crore, reflecting resilience in key markets such as the US and Europe.
Key Highlights:
- Revenue Growth: Revenues for Q2FY26 rose to ₹8,286 crore from ₹7,796 crore in the prior year.
- Profit: Net profit grew modestly to ₹848 crore from ₹817 crore.
- EPS: Earnings per share increased 3.8% to ₹14.48.
- Market Performance: US formulations contributed 43.9% of revenues, growing 3.1%. European markets saw 17.8% growth, while growth markets increased 8.7%.
- EBITDA and Margins: EBITDA increased 7.1% to ₹1,678 crore, with a 20.3% margin.
- R&D: Continued focus on innovation with ₹414 crore spent on research and development.
- Strategic Remarks: Management highlighted balanced growth and profitability with ongoing strategic initiatives on track.
Financial Highlights:
- Revenues for the quarter rose 6.29% year on year to ₹8,286 crore, up from ₹7,796 crore.
- Total expenses increased by 6.05% to ₹7,132 crore compared to ₹6,725 crore last year.
- Consolidated net profit grew 3.79% to ₹848 crore, higher than ₹817 crore for the same quarter previously.
- Earnings per share increased by 3.80% to ₹14.48 from ₹13.95.
The company continues to benefit from steady demand in key regulated markets including the US and Europe. Operational efficiencies and a diverse product portfolio have helped maintain profitability amid evolving industry dynamics.
Strategic Outlook:
Aurobindo Pharma is focused on leveraging its R&D capabilities and market diversification to sustain growth. Its commitment to innovation, compliance, and expanding global footprints positions the company well for long-term value creation in the competitive pharmaceutical landscape.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.
Most Popular
Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript
Cochin Shipyard Limited (NSE:COCHINSHIP) Q4 FY22 Earnings Concall dated May. 26, 2022 Corporate Participants: Madhu S Nair -- Chairman & Managing Director Jose V J -- Director Finance Analysts: Vastupal Shah
All you need to know about Antony Waste Handling Cell in one article
Can you guess the name of the company that was listed during the IPO frenzy in 2020 and is the second largest player in the Indian municipal waste management industry?
Demystifying the Leading Non-Ferrous Recycling Company of India
“Hey, how is the market doing today?” “Oh!, its falling tremendously since morning” I am sure news like these might be a common topic of discussion for you nowadays. Interestingly,